Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-01-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
第四届监事会第四十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company regarding several internal decisions such as the completion of certain fundraising projects, approval of daily related-party transactions for 2023, and application for bank credit facilities and guarantees. It includes voting results and confirms compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a formal announcement of board-level decisions and approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1460 characters), and it is not an announcement of a report publication or a certification letter, so RNS or RPA are less appropriate.
2023-01-11 Chinese
关于部分募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the completion of certain fundraising investment projects and the permanent allocation of surplus raised funds to working capital. It details the use and management of funds raised through convertible bonds, the approval process by the board and supervisory committees, and the need for shareholder approval. The document is a formal announcement about the use of raised capital and related corporate governance steps, not a full financial report or audit. It is not a full annual or interim report, nor an earnings release or call transcript. It is also not a proxy statement or voting result announcement. The document fits best as a Capital/Financing Update (CAP) because it concerns the use and reallocation of funds raised through convertible bonds and related corporate approvals.
2023-01-11 Chinese
独立董事关于公司第四届董事会第四十五次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion on a specific agenda item related to the company's 2023 anticipated related party transactions. It references regulatory guidelines and company governance documents but does not contain financial statements or detailed financial data. The document is short (493 characters) and serves as a formal opinion or announcement related to board matters rather than a full report or financial disclosure. This fits best under Board/Management Information (MANG), which covers announcements related to board activities and management decisions.
2023-01-11 Chinese
关于2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding its expected related party transactions for the year 2023. It includes detailed tables of anticipated transaction amounts, descriptions of related parties, and independent directors' opinions on the transactions. The document is a formal disclosure about anticipated related party transactions, which is a regulatory announcement to inform shareholders and the market. It does not contain financial statements, audit opinions, or detailed financial results. It is not a full annual or interim report, nor is it a call transcript or management discussion. The document is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure that does not fit other specific categories.
2023-01-11 Chinese
关于公司申请2023年度银行综合授信额度及为全资子公司提供保证担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for a 2023 annual bank credit facility and guarantee for its wholly-owned subsidiary. It includes details about the credit amount, guarantee terms, board and supervisory opinions, and compliance with regulatory requirements. The document is relatively short (3420 characters) and focuses on financing and guarantee arrangements rather than presenting financial statements or detailed financial performance. It is not a full financial report, audit report, or earnings release. It is an update on capital/financing activities, specifically about credit facilities and guarantees. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-01-11 Chinese
中航证券有限公司关于健帆生物科技集团股份有限公司部分募投项目结项并将节余募集资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中航证券有限公司) regarding the completion of certain fundraising investment projects and the permanent supplementation of surplus raised funds into working capital by 健帆生物科技集团股份有限公司. It references regulatory guidelines on fundraising management, details the fundraising amount, usage, project completion status, and approvals by the board, independent directors, and supervisory board. The document is not a full financial report but a regulatory compliance and verification statement related to fundraising and capital use. It does not contain financial statements or earnings data but focuses on fundraising project completion and fund usage verification. Given the content and length (3755 characters), it is not an announcement of a report publication but a regulatory filing related to fundraising and capital management. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-01-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.